Your Liver Function Test can reveal important clues about liver health. Learn what common LFT numbers mean and when abnormal ...
Fezolinetant is associated with a hepatic adverse event reporting signal characterized primarily by transaminase elevations rather than clinically overt liver injury.
(NYSE: PFE) today announced detailed progression-free and overall survival results from Cohort 3, a randomized cohort of the Phase 3 BREAKWATER trial, evaluating BRAFTOVI ® (encorafenib) in ...
At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of ...
Pharmacokinetic and pharmacodynamic data support quarterly subcutaneous BRIUMVI dosing regimen currently under evaluation in fully enrolled Phase ...
Median overall survival, a secondary endpoint, reached nearly 3.5 years with Johnson & Johnson's RYBREVANT® plus LAZCLUZE® in atypical EGFR-mutated disease Consistent ...
These post-hoc analyses demonstrate that BRIUMVI provided significant and consistent improvements across multiple clinical and MRI endpoints compared to teriflunomide in patients who had not received ...
The U.S. FDA's Center for Drug Evaluation and Research said on Wednesday it has accepted a letter of intent for an ...
- Late-breaking VISTAS results demonstrate rapid, sustained, and clinically meaningful reductions in pruritus with volixibat in primary sclerosing cholangitis (PSC) - Late-breaking Phase 2b AZURE-1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results